Cargando…
Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
Patients with unresectable hepatic metastases, from uveal or ocular melanoma, are challenging to treat with an overall poor prognosis. Although over the past decade significant advances in systemic therapies have been made, metastatic disease to the liver, especially from uveal melanoma, continues t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480350/ https://www.ncbi.nlm.nih.gov/pubmed/33372814 http://dx.doi.org/10.1177/1073274820983019 |
_version_ | 1784576448867074048 |
---|---|
author | Carr, Michael J. Sun, James Cohen, Jonathan B. Liu, Jinhong Serdiuk, Andrew A. Stewart, Stephen R. Doobay, Navin Duclos, Andrew Seal, David A. Choi, Junsung Zager, Jonathan S. |
author_facet | Carr, Michael J. Sun, James Cohen, Jonathan B. Liu, Jinhong Serdiuk, Andrew A. Stewart, Stephen R. Doobay, Navin Duclos, Andrew Seal, David A. Choi, Junsung Zager, Jonathan S. |
author_sort | Carr, Michael J. |
collection | PubMed |
description | Patients with unresectable hepatic metastases, from uveal or ocular melanoma, are challenging to treat with an overall poor prognosis. Although over the past decade significant advances in systemic therapies have been made, metastatic disease to the liver, especially from uveal melanoma, continues to be a poor prognosis. Percutaneous hepatic perfusion (PHP) is a safe, viable treatment option for these patients. PHP utilizes high dose chemotherapy delivered directly to the liver while minimizing systemic exposure and can be repeated up to 6 times. Isolation of the hepatic vasculature with a double-balloon catheter allows for high concentration cytotoxic therapy to be administered with minimal systemic adverse effects. A detailed description of the multidisciplinary treatment protocol used at an institution with over 12 years of experience is discussed and recommendations are given. A dedicated team of a surgical or medical oncology, interventional radiology, anesthesiology and a perfusionist allows PHP to be repeatedly performed as a safe treatment strategy for unresectable hepatic metastases. |
format | Online Article Text |
id | pubmed-8480350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84803502021-09-30 Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases Carr, Michael J. Sun, James Cohen, Jonathan B. Liu, Jinhong Serdiuk, Andrew A. Stewart, Stephen R. Doobay, Navin Duclos, Andrew Seal, David A. Choi, Junsung Zager, Jonathan S. Cancer Control Technical Note Patients with unresectable hepatic metastases, from uveal or ocular melanoma, are challenging to treat with an overall poor prognosis. Although over the past decade significant advances in systemic therapies have been made, metastatic disease to the liver, especially from uveal melanoma, continues to be a poor prognosis. Percutaneous hepatic perfusion (PHP) is a safe, viable treatment option for these patients. PHP utilizes high dose chemotherapy delivered directly to the liver while minimizing systemic exposure and can be repeated up to 6 times. Isolation of the hepatic vasculature with a double-balloon catheter allows for high concentration cytotoxic therapy to be administered with minimal systemic adverse effects. A detailed description of the multidisciplinary treatment protocol used at an institution with over 12 years of experience is discussed and recommendations are given. A dedicated team of a surgical or medical oncology, interventional radiology, anesthesiology and a perfusionist allows PHP to be repeatedly performed as a safe treatment strategy for unresectable hepatic metastases. SAGE Publications 2020-12-29 /pmc/articles/PMC8480350/ /pubmed/33372814 http://dx.doi.org/10.1177/1073274820983019 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Technical Note Carr, Michael J. Sun, James Cohen, Jonathan B. Liu, Jinhong Serdiuk, Andrew A. Stewart, Stephen R. Doobay, Navin Duclos, Andrew Seal, David A. Choi, Junsung Zager, Jonathan S. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases |
title | Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases |
title_full | Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases |
title_fullStr | Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases |
title_full_unstemmed | Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases |
title_short | Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases |
title_sort | over 12 years single institutional experience performing percutaneous hepatic perfusion for unresectable liver metastases |
topic | Technical Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480350/ https://www.ncbi.nlm.nih.gov/pubmed/33372814 http://dx.doi.org/10.1177/1073274820983019 |
work_keys_str_mv | AT carrmichaelj over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT sunjames over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT cohenjonathanb over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT liujinhong over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT serdiukandrewa over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT stewartstephenr over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT doobaynavin over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT duclosandrew over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT sealdavida over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT choijunsung over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases AT zagerjonathans over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases |